Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 DiabetesGeorge L. Bakris, Rajiv Agarwal, Stefan D. Anker et al.|New England Journal of Medicine|2020Cited by 2.6k
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysisRajiv Agarwal, Gerasimos Filippatos, Bertram Pitt et al.|European Heart Journal|2021Cited by 1.2k
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trialBertram Pitt, Faı̈ez Zannad, Lars Køber et al.|European Heart Journal|2013Cited by 573
The novel non‐steroidal MR antagonist finerenone improves metabolic parameters in high‐fat diet‐fed mice and activates brown adipose tissue via AMPK‐ATGL pathwayVincenzo Marzolla, Massimiliano Caprio, Alessandra Feraco et al.|The FASEB Journal|2020Cited by 69
Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trialHiddo J.L. Heerspink, Janet B. McGill, Andreas L. Birkenfeld et al.|Diabetes Research and Clinical Practice|2023Cited by 57